Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
The study is a multicenter, open-label, randomized controlled clinical study. The purpose of the study is to evaluate the efficacy and safety of apatinib combined with chemotherapy versus chemotherapy in second-line gastric cancer receiving prior anti-PD-1 therapy.
Gastric Cancer|Randomized Controlled Study
DRUG: Apatinib
Progression Free Survival [PFS], From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months, 36 months
Objective tumor response rate [ORR], ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments., 1year|disease control rate [DCR], Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1（RECIST1.1）, 1year|Duration of response [DoR], Duration of response, 1year|overall survival [OS], OS is defined as the length of time from random assignment to death or to last contact., 3year|Adverse Events [AEs], AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0, 1year
60 patients who meet the inclusion criteria will receive apatinib combine with chemotherapy or chemotherapy until the disease progresses or intolerable.

Apatinib: initial dose: 500mg,oral,once a day, after meal (try to take the medicine at the same time each day)